Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center
•Data includes 20-years oncological outcomes after radical prostatectomy•Data includes the largest retrospective radical prostatectomy cohort from Europe•In low-risk patients, 20-years cancer-specific survival was 90.1%•In intermediate risk patients, 20-years cancer-specific survival was 83.2%•In hi...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2021-12, Vol.39 (12), p.830.e17-830.e26 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 830.e26 |
|---|---|
| container_issue | 12 |
| container_start_page | 830.e17 |
| container_title | Urologic oncology |
| container_volume | 39 |
| creator | Würnschimmel, Christoph Wenzel, Mike Wang, Nuowei Tian, Zhe Karakiewicz, Pierre I. Graefen, Markus Huland, Hartwig Tilki, Derya |
| description | •Data includes 20-years oncological outcomes after radical prostatectomy•Data includes the largest retrospective radical prostatectomy cohort from Europe•In low-risk patients, 20-years cancer-specific survival was 90.1%•In intermediate risk patients, 20-years cancer-specific survival was 83.2%•In high/very high-risk patients, 20-years cancer-specific survival was 69.6%/60.8%
Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.
Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.
Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.
Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up. |
| doi_str_mv | 10.1016/j.urolonc.2021.04.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2538047552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143921001885</els_id><sourcerecordid>2538047552</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-4eb3658942ff6c6622ef0af87040950248ac6ce8a7aacc001b853251e34f51753</originalsourceid><addsrcrecordid>eNqFkE9P3DAQxa2Kqiy0H6GVj70k-G_i7QVVqCxIKyFV7dnyOmPwKompnSAtn74Du-yV01ieN_Pe_Aj5ylnNGW8utvWcU59GXwsmeM1UzST_QBbctLISatmc4Ju1puJKLk_JWSlbxrgynH8ip1KxpVBGLUj-7broXU8fcyqTm8BPadjRkDLtE_7HZ-iOPerd6CH_oIJVO3CZoj1muH9dkObJpwEKDTkN1NEV5MGN9CHeP1RPqZ8HHIdxgvyZfAyuL_DlUM_J3-tff65uqvXd6vbq57rystFTpWCD1SyVCKHxTSMEBOaCaRmG1wzjO994MK51znu8bWO0FJqDVEHzVstz8n2_F-P_m6FMdojFQ9-7EdJcrNDSMNVqLVCq91KPl5YMwT7mOLi8s5zZF9x2aw-47Qtuy5RF3Dj37WAxbwbojlNvfFFwuRcAHvoUIdviIyDELmZEbbsU37H4D-cilNY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2538047552</pqid></control><display><type>article</type><title>Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Würnschimmel, Christoph ; Wenzel, Mike ; Wang, Nuowei ; Tian, Zhe ; Karakiewicz, Pierre I. ; Graefen, Markus ; Huland, Hartwig ; Tilki, Derya</creator><creatorcontrib>Würnschimmel, Christoph ; Wenzel, Mike ; Wang, Nuowei ; Tian, Zhe ; Karakiewicz, Pierre I. ; Graefen, Markus ; Huland, Hartwig ; Tilki, Derya</creatorcontrib><description>•Data includes 20-years oncological outcomes after radical prostatectomy•Data includes the largest retrospective radical prostatectomy cohort from Europe•In low-risk patients, 20-years cancer-specific survival was 90.1%•In intermediate risk patients, 20-years cancer-specific survival was 83.2%•In high/very high-risk patients, 20-years cancer-specific survival was 69.6%/60.8%
Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.
Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.
Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.
Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2021.04.031</identifier><identifier>PMID: 34092484</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Germany ; Humans ; Long-term outcome ; Male ; Middle Aged ; Oncological outcomes ; Prostate cancer ; Prostatectomy - methods ; Prostatic Neoplasms - surgery ; Radical prostatectomy ; Survival ; Survival Rate ; Treatment Outcome</subject><ispartof>Urologic oncology, 2021-12, Vol.39 (12), p.830.e17-830.e26</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-4eb3658942ff6c6622ef0af87040950248ac6ce8a7aacc001b853251e34f51753</citedby><cites>FETCH-LOGICAL-c365t-4eb3658942ff6c6622ef0af87040950248ac6ce8a7aacc001b853251e34f51753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1078143921001885$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34092484$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Würnschimmel, Christoph</creatorcontrib><creatorcontrib>Wenzel, Mike</creatorcontrib><creatorcontrib>Wang, Nuowei</creatorcontrib><creatorcontrib>Tian, Zhe</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>Huland, Hartwig</creatorcontrib><creatorcontrib>Tilki, Derya</creatorcontrib><title>Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•Data includes 20-years oncological outcomes after radical prostatectomy•Data includes the largest retrospective radical prostatectomy cohort from Europe•In low-risk patients, 20-years cancer-specific survival was 90.1%•In intermediate risk patients, 20-years cancer-specific survival was 83.2%•In high/very high-risk patients, 20-years cancer-specific survival was 69.6%/60.8%
Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.
Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.
Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.
Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.</description><subject>Aged</subject><subject>Germany</subject><subject>Humans</subject><subject>Long-term outcome</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oncological outcomes</subject><subject>Prostate cancer</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Radical prostatectomy</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9P3DAQxa2Kqiy0H6GVj70k-G_i7QVVqCxIKyFV7dnyOmPwKompnSAtn74Du-yV01ieN_Pe_Aj5ylnNGW8utvWcU59GXwsmeM1UzST_QBbctLISatmc4Ju1puJKLk_JWSlbxrgynH8ip1KxpVBGLUj-7broXU8fcyqTm8BPadjRkDLtE_7HZ-iOPerd6CH_oIJVO3CZoj1muH9dkObJpwEKDTkN1NEV5MGN9CHeP1RPqZ8HHIdxgvyZfAyuL_DlUM_J3-tff65uqvXd6vbq57rystFTpWCD1SyVCKHxTSMEBOaCaRmG1wzjO994MK51znu8bWO0FJqDVEHzVstz8n2_F-P_m6FMdojFQ9-7EdJcrNDSMNVqLVCq91KPl5YMwT7mOLi8s5zZF9x2aw-47Qtuy5RF3Dj37WAxbwbojlNvfFFwuRcAHvoUIdviIyDELmZEbbsU37H4D-cilNY</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Würnschimmel, Christoph</creator><creator>Wenzel, Mike</creator><creator>Wang, Nuowei</creator><creator>Tian, Zhe</creator><creator>Karakiewicz, Pierre I.</creator><creator>Graefen, Markus</creator><creator>Huland, Hartwig</creator><creator>Tilki, Derya</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center</title><author>Würnschimmel, Christoph ; Wenzel, Mike ; Wang, Nuowei ; Tian, Zhe ; Karakiewicz, Pierre I. ; Graefen, Markus ; Huland, Hartwig ; Tilki, Derya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-4eb3658942ff6c6622ef0af87040950248ac6ce8a7aacc001b853251e34f51753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Germany</topic><topic>Humans</topic><topic>Long-term outcome</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oncological outcomes</topic><topic>Prostate cancer</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Radical prostatectomy</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Würnschimmel, Christoph</creatorcontrib><creatorcontrib>Wenzel, Mike</creatorcontrib><creatorcontrib>Wang, Nuowei</creatorcontrib><creatorcontrib>Tian, Zhe</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>Huland, Hartwig</creatorcontrib><creatorcontrib>Tilki, Derya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Würnschimmel, Christoph</au><au>Wenzel, Mike</au><au>Wang, Nuowei</au><au>Tian, Zhe</au><au>Karakiewicz, Pierre I.</au><au>Graefen, Markus</au><au>Huland, Hartwig</au><au>Tilki, Derya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>39</volume><issue>12</issue><spage>830.e17</spage><epage>830.e26</epage><pages>830.e17-830.e26</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>•Data includes 20-years oncological outcomes after radical prostatectomy•Data includes the largest retrospective radical prostatectomy cohort from Europe•In low-risk patients, 20-years cancer-specific survival was 90.1%•In intermediate risk patients, 20-years cancer-specific survival was 83.2%•In high/very high-risk patients, 20-years cancer-specific survival was 69.6%/60.8%
Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.
Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.
Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.
Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34092484</pmid><doi>10.1016/j.urolonc.2021.04.031</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2021-12, Vol.39 (12), p.830.e17-830.e26 |
| issn | 1078-1439 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2538047552 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Germany Humans Long-term outcome Male Middle Aged Oncological outcomes Prostate cancer Prostatectomy - methods Prostatic Neoplasms - surgery Radical prostatectomy Survival Survival Rate Treatment Outcome |
| title | Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A32%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radical%20prostatectomy%20for%20localized%20prostate%20cancer:%2020-year%20oncological%20outcomes%20from%20a%20German%20high-volume%20center&rft.jtitle=Urologic%20oncology&rft.au=W%C3%BCrnschimmel,%20Christoph&rft.date=2021-12&rft.volume=39&rft.issue=12&rft.spage=830.e17&rft.epage=830.e26&rft.pages=830.e17-830.e26&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2021.04.031&rft_dat=%3Cproquest_cross%3E2538047552%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2538047552&rft_id=info:pmid/34092484&rft_els_id=S1078143921001885&rfr_iscdi=true |